| |
| |
|
| Insider
Information: |
Evnin Luke |
| Relationship: |
10% Owner |
| City: |
Boston |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
15 |
|
| Direct
Shares |
330,044 |
|
|
Indirect Shares
|
35,767,143 |
|
|
| Direct
Value |
$449,921 |
|
|
|
Indirect Value
|
$125,579,860 |
|
|
| Total
Shares |
36,097,187 |
|
|
| Total
Value |
$126,029,782 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
1
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-1.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -18.7%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Oscient Pharmaceuticals Corp |
OSCIQ |
Director |
|
0 |
2006-01-05 |
2,272,935 |
Premium* |
|
|
Idenix Pharmaceuticals Inc |
IDIX |
10% Owner |
2004-07-27 |
0 |
2004-07-27 |
4,797,991 |
Premium* |
|
|
Rigel Pharmaceuticals Inc |
RIGL |
10% Owner |
2004-07-02 |
0 |
2004-07-02 |
1,833,597 |
Premium* |
|
|
iPass Inc |
IPAS |
10% Owner |
2004-02-09 |
26,043 |
2004-02-09 |
262,533 |
Premium* |
|
|
Hemosense Inc |
HEM |
10% Owner |
2005-07-01 |
0 |
2007-11-06 |
0 |
Premium* |
|
|
American Cryostem Corporation |
CRYO |
10% Owner |
2005-07-13 |
0 |
2005-07-19 |
2,931,531 |
Premium* |
|
|
Radius Health Inc. |
RDUS |
Former 10% stockholder |
|
0 |
2016-09-27 |
3,887,502 |
Premium* |
|
|
Pacira Pharmaceuticals, Inc. |
PCRX |
Director |
2013-06-13 |
0 |
2013-06-13 |
824,255 |
Premium* |
|
|
Syndax Pharmaceuticals Inc |
SNDX |
Director, 10% Owner |
2016-03-08 |
0 |
2016-03-08 |
2,168,691 |
Premium* |
|
|
Harpoon Therapeutics, Inc. |
HARP |
Former 10% Owner |
2019-02-12 |
0 |
2021-04-15 |
3,220,844 |
Premium* |
|
|
Repare Therapeutics Inc. |
RPTX |
10% Owner |
2020-06-23 |
0 |
2020-06-23 |
3,003,772 |
Premium* |
|
|
Oncorus, Inc. |
ONCR |
Director, 10% Owner |
|
0 |
2020-10-06 |
2,492,843 |
Premium* |
|
|
Turmeric Acquisition Corp. |
TMPM |
Chief Executive Officer |
2020-10-20 |
0 |
2020-10-20 |
415,500 |
Premium* |
|
|
Werewolf Therapeutics, Inc. |
HOWL |
Director, 10% Owner |
|
0 |
2021-05-04 |
4,284,172 |
Premium* |
|
|
Tcr2 Therapeutics Inc. |
TCRR |
10% Owner |
2023-05-22 |
304,001 |
2023-05-22 |
3,370,977 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
107 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 5 of 5
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| RIGL |
Rigel Pharmaceuticals Inc |
10% Owner |
– – • |
2004-07-02 |
4 |
S |
$14.88 |
$116,786 |
I/I |
(7,847) |
1,833,597 |
|
- |
|
| RPTX |
Repare Therapeutics Inc. |
10% Owner |
– – • |
2020-06-23 |
4 |
B |
$20.00 |
$5,000,000 |
I/I |
250,000 |
3,003,772 |
1.5 |
- |
|
| RPTX |
Repare Therapeutics Inc. |
10% Owner |
– – • |
2020-06-23 |
4 |
A |
$0.00 |
$0 |
I/I |
2,753,772 |
2,753,772 |
0 |
- |
|
| SNDX |
Syndax Pharmaceuticals In... |
Director |
– • • |
2016-03-08 |
4 |
A |
$0.00 |
$0 |
I/I |
2,168,691 |
2,168,691 |
0 |
- |
|
| TCRR |
Tcr2 Therapeutics Inc. |
10% Owner |
– – • |
2023-05-22 |
4 |
S |
$1.88 |
$131,920 |
D/D |
(70,170) |
304,001 |
0 |
% |
|
| TCRR |
Tcr2 Therapeutics Inc. |
10% Owner |
– – • |
2023-05-22 |
4 |
OE |
$0.74 |
$131,919 |
D/D |
178,269 |
374,171 |
0 |
- |
|
| TMPM |
Turmeric Acquisition Corp... |
Chief Executive Officer |
• – – |
2020-10-20 |
4 |
A |
$10.00 |
$4,155,000 |
I/I |
415,500 |
415,500 |
0 |
- |
|
107 Records found
|
|
Page 5 of 5 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
